News from alpha tau medical A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 22, 2022, 16:01 ET Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT™

Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that ...

Jun 16, 2022, 16:01 ET Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended Radioactive License with Increased Capacity at Lawrence, MA Site

Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...

Jun 08, 2022, 09:10 ET Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC

Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha ...

Jun 07, 2022, 16:03 ET Alpha Tau Announces Resignation of Gary Leibler from its Board of Directors

Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy ...

May 26, 2022, 16:05 ET Alpha Tau Medical Announces First Quarter 2022 Financial Results and Provides Corporate Update

Alpha Tau Medical Ltd. (NASDAQ: DRTS) (NASDAQ: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy ...

May 23, 2022, 09:00 ET First Alpha DaRT Patients Treated in France as Part of Alpha DaRT™ Multicenter Skin Cancer Trial

Alpha Tau Medical (Nasdaq: DRTS) (Nasdaq: DRTSW), the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT™, announced today that...

Mar 28, 2022, 08:00 ET Alpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update

Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy ...

Mar 21, 2022, 16:05 ET Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors

Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of ...

Feb 16, 2022, 08:00 ET Alpha DaRT Cancer Treatment Wins the Quality "Innovation of Innovations" Award for 2021

Alpha Tau Medical is pleased to announce that its innovative alpha radiation cancer therapy – the Alpha DaRT™ has been awarded the Quality Innovation ...

Jan 20, 2022, 06:45 ET Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulation in the Treatment of Breast Cancer

Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has signed...

Jan 10, 2022, 07:00 ET Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT™ in Malignant Skin & Soft Tissue Cancers, Showing Complete Response in All Ten Treated Tumors at Approximately 12 Weeks and No Product-Related Serious Adverse Events

Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that all ten...

Jan 03, 2022, 07:00 ET Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer

Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has been...

Nov 03, 2021, 13:00 ET Alpha Tau Announces Enrollment of First Patient in Combination Trial of Alpha DaRT™ and Pembrolizumab (Keytruda®)

Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that it has enrolled ...

Oct 25, 2021, 08:25 ET Alpha Tau Announces Completion of Enrollment in First US Clinical Trial of Alpha DaRT™ and Achievement of First Primary Objective

Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that its US pilot...

Oct 08, 2021, 08:19 ET Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM

Alpha Tau Medical, the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, is pleased to announce that it has received...

Jul 06, 2021, 15:05 ET First Alpha DaRT™ Patient Treated in the US as Part of Pilot Multicenter Skin Cancer Trial

Alpha Tau Medical, the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT™, announced today that the first participant in its US...

Jun 08, 2021, 12:18 ET Alpha Tau Receives Breakthrough Device Designation from the FDA for Alpha DaRT™

Alpha Tau Medical, the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT,TM is pleased to announce that it has received a...

Jan 12, 2021, 11:00 ET Alpha Tau Medical Announces Appointment of Peter Melnyk as New Board Member

Alpha Tau Medical, the developer of breakthrough Alpha DaRT (Diffusing alpha-emitters Radiation Therapy), is pleased to announce the appointment of...

Jun 04, 2020, 07:00 ET Alpha Tau Medical Announces Successful Completion of New $26 Million Funding Round

Alpha Tau Medical, the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT, is pleased to announce the closing of a Series B equity...

Nov 26, 2019, 08:24 ET Alpha Tau Announces the Publication of Exceptional Clinical Data from Alpha DaRT, its Novel Alpha Radiotherapy for Solid Tumors

Alpha Tau Medical is pleased to announce the publication of the results of its first clinical trial of Alpha DaRT™, a novel alpha radiation cancer...

Sep 27, 2019, 07:00 ET Alpha Tau Medical Appoints Professor Yona Keisari as Chief Scientific Officer

The cancer biotech company Alpha Tau Medical, announced today the appointment of Prof. Yona Keisari as Chief Scientific Officer. As a leader in the...

Sep 04, 2019, 07:00 ET Alpha Tau Medical Appoints Jefferson University Radiation Oncologist Robert Den as Chief Medical Officer

Alpha Tau Medical, developer of the breakthrough alpha radiation cancer therapy Alpha DaRT, announced today the appointment of Dr. Robert B. Den, MD, ...

Apr 11, 2019, 07:30 ET Breakthrough Cancer Therapy Developer, Alpha Tau, Awarded ISO 13485 Certificate for Quality Management of Medical Devices

Alpha Tau Medical, developer of the breakthrough alpha radiation cancer therapy, Alpha DaRT, announced today that it has obtained ISO 13485:2016...

Mar 26, 2019, 07:30 ET Cancer Biotech Firm Alpha Tau Medical Appoints Raphi Levy of Goldman Sachs as Chief Financial Officer

Alpha Tau Medical, developer of the breakthrough alpha radiation cancer therapy, Alpha DaRT, announced today that Mr. Raphi Levy will be joining...

Sep 05, 2018, 07:00 ET Israeli MedTech Start-up, Alpha Tau Medical, Raises $29 Million in Private Financing to Cure Cancer

Alpha Tau Medical, developer of a breakthrough alpha radiation cancer therapy, announced today that it has secured $29 million in private financing....